Evidence map›Paper›PMID 20810659›Full record

ArticleThe Journal of biological chemistry2010

Cytoplasmic body component TRIM5{alpha} requires lipid-enriched microdomains for efficient HIV-1 restriction.

Seiga Ohmine, Ryuta Sakuma, Toshie Sakuma, Tayaramma Thatava, Gonzalo P Solis, Yasuhiro Ikeda

Open access · hybridAbstract read
In one paragraph

Article in The Journal of biological chemistry, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.7field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 10 citations in OpenAlex.

  1. Sequence Analysis ofFrontiers in veterinary science · 2022
    Article
  2. Article
  3. Article
  4. Ex vivo gene therapy for HIV-1 treatment.Human molecular genetics · 2011
    Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Seiga OhmineDepartment of Molecular Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA.
Ryuta Sakuma
Toshie Sakuma
Tayaramma Thatava
Gonzalo P Solis
Yasuhiro Ikeda
Mayo Clinic · USUniversity of Konstanz · DE

Funding

TRIM5alpha-mediated block of HIV-1 productionR56AI074363 · NIAID · MAYO CLINIC ROCHESTER · PI IKEDA, YASUHIRO · 2008 to 2008
$340k
NIAID NIH HHS 1R56AI074363-01A1NIAID NIH HHS R56 AI074363
6 · The paper itself

Abstract

TRIM5α is a member of the tripartite motif (TRIM) family of proteins and affects both early and late phases of the retroviral life cycle. Although TRIM5α multimerizes to form cytoplasmic bodies, which are thought to play an important role in viral restriction, the identity of TRIM5α-containing cytoplasmic bodies remains elusive. To better understand TRIM5α cytoplasmic body constituents and the cellular proteins that could be involved in the TRIM5α-mediated antiviral activities, we sought TRIM5α-binding factors. We identified a lipid microdomain protein flotillin-1/Reggie-2 as an interacting partner of TRIM5α via co-immunoprecipitation. Immunohistochemistry studies confirmed the co-localization of rhesus monkey TRIM5α (TRIM5αrh) cytoplasmic bodies with flotillin-1/Reggie-2. Caveolin-1, another lipid microdomain-associated protein, also co-localized with TRIM5α cytoplasmic bodies. Intriguingly, disruption of cellular cholesterol by cyclodextrin perturbed TRIM5α cytoplasmic body formation. Furthermore, lipid starvation partially relieved the endogenous post-entry restriction of HIV-1 infection, which could be subsequently restored by lipid repletion. These observations indicate the involvement of cellular lipids in TRIM5α-mediated antiviral activities. Given that many viruses utilize cellular lipid microdomains for viral entry and assembly, it is plausible that lipid-enriched domains provide microenvironments where TRIM5α recognizes retroviral components.

Indexed as

Virus InternalizationAnimalsAntiviral Restriction FactorsCarrier ProteinsCaveolin 1Cell LineCyclodextrinsHIV-1HIV InfectionsHumansMacaca mulattaMembrane MicrodomainsMembrane ProteinsSpecies SpecificityTripartite Motif ProteinsUbiquitin-Protein LigasesAntiviral Restriction FactorsCarrier ProteinsCAV1 protein, humanCaveolin 1CyclodextrinsflotillinsMembrane ProteinsTRIM5 protein, humanTripartite Motif ProteinsUbiquitin-Protein Ligases

Identifiers

PMID20810659
PMCPMC2966066
OpenAlexW2072015561

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.